{"version": "https://jsonfeed.org/version/1.1", "title": "Sharemaestro Newsreel: United States Biotechnology news", "home_page_url": "https://sharemaestro.com/newsreel/us/healthcare/biotechnology/", "feed_url": "https://sharemaestro.com/newsreel/us/healthcare/biotechnology/feed.json", "description": "Latest Biotechnology company headlines from United States, newest first, with source links and direct routes to company research and sentiment.", "language": "en", "items": [{"id": "source:967a22b511749e5b0f440ccd025638bc3d2991c76bb33f51e688e92a5254d6d1", "url": "https://seekingalpha.com/news/4633430-satellos-bioscience-inc-gaap-eps-of-0_56?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "external_url": "https://seekingalpha.com/news/4633430-satellos-bioscience-inc-gaap-eps-of-0_56?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "title": "Satellos Bioscience Inc. GAAP EPS of -$0.56", "content_text": "* Satellos Bioscience Inc. press release [https://seekingalpha.com/filing/309950026] (MSCL:CA [https://seekingalpha.com/symbol/MSCL:CA]): Q2 GAAP EPS of -$0.56. * Research and development expenses increased by $5,200 to $9,635 for the three months ended June 30, 2026, compared to $4,435 for the three months ended June 30, 2025, and by $7,968 to $16,945 for the six months ended June 30, 2026, compared to $8,977 for the six months ended June 30, 2025. MORE ON SATELLOS BIOSCIENCE INC. * Historical earnings data for Satellos Bioscience Inc. [https://seekingalpha.com/symbol/MSCL:CA/earnings] * Fina", "date_published": "2026-08-14T16:46:42+00:00", "authors": [{"name": "seekingalpha.com"}], "tags": ["Earnings", "MSLE"], "_sharemaestro": {"country": "United States", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MSLE", "name": "Satellos Bioscience Inc. Common Stock", "sentiment_url": "https://sharemaestro.com/sentiment/fbb34216-4127-4ac5-80fe-93adab30edc9/"}]}}, {"id": "source:20d822dcf8f64df6de972cf1de8abdf9f2bcce5b3703890b29b0625864432f7b", "url": "https://www.nasdaq.com/articles/vistagen-reports-narrower-q1-loss-plans-fda-meeting-fasedienol-development-path", "external_url": "https://www.nasdaq.com/articles/vistagen-reports-narrower-q1-loss-plans-fda-meeting-fasedienol-development-path", "title": "Vistagen Reports Narrower Q1 Loss; Plans FDA Meeting On Fasedienol Development Path", "content_text": "(RTTNews) - Vistagen Therapeutics Inc. (VTGN), a late clinical-stage biopharmaceutical company developing intranasal pherine therapies for neuropsychiatric and other disorders, reported first quarter fiscal 2027 results and provided a corporate update. Vistagen is developing rapid-onset intranasal pherine product candidates designed to target nose-to-brain neurocircuitry. Its lead programs include fasedienol for social anxiety disorder, itruvone for major depressive disorder and refisolone for menopausal hot flashes. First Quarter Highlights For the first quarter ended June 30, 2026, net loss ", "date_published": "2026-08-14T16:36:33+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Earnings", "VTGN"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "VTGN", "name": "VistaGen Therapeutics Inc", "sentiment_url": "https://sharemaestro.com/sentiment/de72e54f-253a-4fd9-9a77-4075aac4d646/"}]}}, {"id": "source:b2bbec729a22b1a035f22dd39d49b0efcfc496e51408830ce3fdb5a317e110e8", "url": "https://www.nasdaq.com/articles/jasper-therapeutics-secures-132m-financing-advances-post-kira-clinical-pipeline", "external_url": "https://www.nasdaq.com/articles/jasper-therapeutics-secures-132m-financing-advances-post-kira-clinical-pipeline", "title": "Jasper Therapeutics Secures $132M In Financing; Advances Post-Kira Clinical Pipeline", "content_text": "(RTTNews) - Jasper Therapeutics Inc. (JSPR), a clinical-stage biotechnology company focused on immune-mediated diseases, reported second quarter 2026 financial results and provided a corporate update following the completion of its acquisition of Kira Pharmaceuticals. The combined company is advancing a portfolio of clinical-stage therapies targeting immunologically driven disorders, including KP-104, briquilimab and KP-701. Q2 2026 Performance: Cash and cash equivalents totaled $7.3 million as of June 30, 2026. Research and development (R&D) expenses were $5.1 million, while general and admin", "date_published": "2026-08-14T16:29:11+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Deals and strategy", "JSPR"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "JSPR", "name": "Jasper Therapeutics Inc", "sentiment_url": "https://sharemaestro.com/sentiment/e6bc52d4-759d-4082-a252-e3fd6873465d/"}]}}, {"id": "source:a6a82bed717dc383037e1f5518f023b0b0cb258d52b3ac173ddbac978b207031", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-drts/alpha-tau-medical/news/is-alpha-tau-medicals-drts-steepening-loss-curve-reframing-i/amp", "external_url": "https://simplywall.st/stocks/us/healthcare/nasdaq-drts/alpha-tau-medical/news/is-alpha-tau-medicals-drts-steepening-loss-curve-reframing-i/amp", "title": "Is Alpha Tau Medical\u2019s (DRTS) Steepening Loss Curve Reframing Its High-Risk Innovation Strategy?", "content_text": "Alpha Tau Medical (DRTS) reported a significant widening of its net loss to US$68.75 million in the first half of 2026, up from US$18.81 million a year prior, leading to increased concerns about its funding risk. Despite the company's focus on clinical progress for its Alpha DaRT cancer treatment, its pre-revenue status and mounting losses, compounded by a withdrawn US$75 million offering, intensify the pressure on its financial strategy. Investors are urged to consider these financial challenges alongside the company's valuation, as its shares may be overvalued according to some analyses.", "date_published": "2026-08-14T15:42:38+00:00", "authors": [{"name": "Simply Wall Street"}], "tags": ["Earnings", "DRTS"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "DRTS", "name": "Alpha Tau Medical Ltd", "sentiment_url": "https://sharemaestro.com/sentiment/604862f7-3d9a-467e-8afd-9810e40ea196/"}]}}, {"id": "source:5d2040891efcf4b0105ae7b4e1d3c9c9a44dd43be100b72547f1c651aff83696", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOZGlNaDdUMDQ1eUdkQ3FTUHZtd0JaZFNPTlI3cWN1ZTh0Wkx5cUN5OXFsSHdOQ0ZNNXZjdTJEckg1RGtrbkNTVllHYkRzWkpqb2lxa3hwZDVMdk10WGdwZ3o4TU9jR1lKLVYtSjBVdzVlRnFodUtReVg1Y09OdFp2cVBENGVkM01zbTlkT0Y2S0dGYUxaa2w4LTA0QVgzZDFIZ2RuSXV2dU04Y0taZ2xkOFZVNlI2Z1E4X3RDaHZsaWozclE?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOZGlNaDdUMDQ1eUdkQ3FTUHZtd0JaZFNPTlI3cWN1ZTh0Wkx5cUN5OXFsSHdOQ0ZNNXZjdTJEckg1RGtrbkNTVllHYkRzWkpqb2lxa3hwZDVMdk10WGdwZ3o4TU9jR1lKLVYtSjBVdzVlRnFodUtReVg1Y09OdFp2cVBENGVkM01zbTlkT0Y2S0dGYUxaa2w4LTA0QVgzZDFIZ2RuSXV2dU04Y0taZ2xkOFZVNlI2Z1E4X3RDaHZsaWozclE?oc=5", "title": "MeiraGTx (NASDAQ:MGTX) Given New $27.00 Price Target at Royal Bank Of Canada", "content_text": "MeiraGTx (NASDAQ:MGTX) Given New $27.00 Price Target at Royal Bank Of Canada", "date_published": "2026-08-14T15:40:26+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Analyst action", "MGTX"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MGTX", "name": "MeiraGTx Holdings PLC", "sentiment_url": "https://sharemaestro.com/sentiment/c17b2e70-74a3-4bc4-a406-6ee0fb32abf1/"}]}}, {"id": "source:fcb617868a80dd26c21a3308e17af41d8529c3a95e080f1f235bb7a4c3d639f4", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOdDY1U2VibkpZSURkdjNkbGw1ajFjSGotS09mQ1NydFYtTExLMWp5RTFNZzZZekVQdXNlREVHLTg5M04zMXA3RzNqbHEyZmxDWWw4SHA1bHVTXzBiaGVnTEpNZ3djMklaM1ZocjRLMUFuV3FoSzZNUmZrZ3hQNVp4ckJSZ3FheUtGLUVsbXdraE1iUDJQdzNpRFNaVktkZw?oc=5", "external_url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOdDY1U2VibkpZSURkdjNkbGw1ajFjSGotS09mQ1NydFYtTExLMWp5RTFNZzZZekVQdXNlREVHLTg5M04zMXA3RzNqbHEyZmxDWWw4SHA1bHVTXzBiaGVnTEpNZ3djMklaM1ZocjRLMUFuV3FoSzZNUmZrZ3hQNVp4ckJSZ3FheUtGLUVsbXdraE1iUDJQdzNpRFNaVktkZw?oc=5", "title": "Nektar Therapeutics (NKTR) Stock Looks Stretched Despite New Phase 3 Trial Launch", "content_text": "Nektar Therapeutics (NKTR) Stock Looks Stretched Despite New Phase 3 Trial Launch", "date_published": "2026-08-14T15:12:17+00:00", "authors": [{"name": "Market source"}], "tags": ["Market update", "NKTR"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "NKTR", "name": "Nektar Therapeutics", "sentiment_url": "https://sharemaestro.com/sentiment/2b54e02b-1441-43ca-8cf6-5798bc73166f/"}]}}, {"id": "source:82ce0997b44f79952cdc69f6acdd4b17d1fdcf8f7fc0bde0d1c3da24b46b3a02", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxOYzJhRXplNVlLUEVYRURQRFNoYTU3N0lDYmZvS3l2V2FhSVl0Y29LSGd1dkN1LXdmaWw4LWc2RzJGQllYSFhrS2M1TWJ1Vk1tU0xET1NQd013MFF5dmZrSmptWmwzZ2hIeXdFV0xVNlBZckZTOHp2NWRGMGptVHVVSFRIams3bHN5dFFKZFJKanJhN2ZxUnhlQVZmZmZQaURkcFI0Rlphc215ajJWbnFMczNMLW9xdVVJdHRlNllDNnQyTERSRGcydg?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxOYzJhRXplNVlLUEVYRURQRFNoYTU3N0lDYmZvS3l2V2FhSVl0Y29LSGd1dkN1LXdmaWw4LWc2RzJGQllYSFhrS2M1TWJ1Vk1tU0xET1NQd013MFF5dmZrSmptWmwzZ2hIeXdFV0xVNlBZckZTOHp2NWRGMGptVHVVSFRIams3bHN5dFFKZFJKanJhN2ZxUnhlQVZmZmZQaURkcFI0Rlphc215ajJWbnFMczNMLW9xdVVJdHRlNllDNnQyTERSRGcydg?oc=5", "title": "Jasper Therapeutics, Inc. 2Q 2026: Net loss $(2.8M), EPS $(0.10) \u2014 10-Q Summary", "content_text": "Jasper Therapeutics, Inc. 2Q 2026: Net loss $(2.8M), EPS $(0.10) \u2014 10-Q Summary", "date_published": "2026-08-14T15:11:03+00:00", "authors": [{"name": "TradingView"}], "tags": ["Earnings", "JSPR"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "JSPR", "name": "Jasper Therapeutics Inc", "sentiment_url": "https://sharemaestro.com/sentiment/e6bc52d4-759d-4082-a252-e3fd6873465d/"}]}}, {"id": "source:765b7ab062038ef677e119f541fc7c916247fa3a83ca6c7bede4bc751bc5989e", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPN2VBcjd5UWhyQlBKMGwzZmhDRkttOHFQS3ZiTm1BRV9SXzJySFNfWms5T2J4eDFKU0VGNGRZRUJrOTl6VUJfemtsY09NUlpnWExxWVYydXBaOTFUX0hfQnhNSzd5UHdJbEU2ZWhEMzBveEZzaDJKVEREUExFOGx3NkM2RU03MmpkZXd2ZXk3YlNuTENpX2NHMEtOV05LUWJ5c2huNVE2TWxieHppVFRXejJMbGlYRjA?oc=5", "external_url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPN2VBcjd5UWhyQlBKMGwzZmhDRkttOHFQS3ZiTm1BRV9SXzJySFNfWms5T2J4eDFKU0VGNGRZRUJrOTl6VUJfemtsY09NUlpnWExxWVYydXBaOTFUX0hfQnhNSzd5UHdJbEU2ZWhEMzBveEZzaDJKVEREUExFOGx3NkM2RU03MmpkZXd2ZXk3YlNuTENpX2NHMEtOV05LUWJ5c2huNVE2TWxieHppVFRXejJMbGlYRjA?oc=5", "title": "Jasper Therapeutics (JSPR) slashes losses, acquires Kira and raises $132M", "content_text": "Jasper Therapeutics (JSPR) slashes losses, acquires Kira and raises $132M", "date_published": "2026-08-14T15:02:01+00:00", "authors": [{"name": "Stock Titan"}], "tags": ["Market update", "JSPR"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "JSPR", "name": "Jasper Therapeutics Inc", "sentiment_url": "https://sharemaestro.com/sentiment/e6bc52d4-759d-4082-a252-e3fd6873465d/"}]}}, {"id": "source:99fb6c2e1dea33d996f72e30b63e3db219640b540a33fac552487fb737c1eaa1", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQWGs0NDdtZUhpdE9fbllocmRaMzlKeWxMY1R5Y19pNU1NSGtTZVVtTWxlYXpkMFJVcDNPVnFTSkxZY25mMnRsY0x6Z2ZtMWdpeGFUazNYa3ZiLWxZSW95cTVzdnh5TDVyTGxOVXlNRHpsX3ZkbjRza2JFM3J6SWtpR2MteGZTQUZLc2lOZGsxQ0ZtSXF2UVRMbWl6OFZpWDFYbGVVLUVHWDgyV0loUTNMcExpaUR2dHRLSGVrZA?oc=5", "external_url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQWGs0NDdtZUhpdE9fbllocmRaMzlKeWxMY1R5Y19pNU1NSGtTZVVtTWxlYXpkMFJVcDNPVnFTSkxZY25mMnRsY0x6Z2ZtMWdpeGFUazNYa3ZiLWxZSW95cTVzdnh5TDVyTGxOVXlNRHpsX3ZkbjRza2JFM3J6SWtpR2MteGZTQUZLc2lOZGsxQ0ZtSXF2UVRMbWl6OFZpWDFYbGVVLUVHWDgyV0loUTNMcExpaUR2dHRLSGVrZA?oc=5", "title": "Nektar Q2 Earnings Beat Estimates, Revenues Lag, Pipeline in Focus", "content_text": "Nektar Therapeutics NKTR reported a loss of $1.23 per share for the second quarter of 2026, much narrower than the Zacks Consensus Estimate of a loss of $2.06. In the year-ago quarter, the company had incurred a loss of $2.95 cents per share. Total revenues in the second quarter came in at $10.1 million, down 9.8% year over year. The reported figure missed the Zacks Consensus Estimate of $11 million. Nektar sold its Huntsville manufacturing facility in December 2024, following which the company no longer records product revenues and lower non-cash royalty revenues. The company's top line curre", "date_published": "2026-08-14T15:02:00+00:00", "authors": [{"name": "TradingView"}], "tags": ["Earnings", "NKTR"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "NKTR", "name": "Nektar Therapeutics", "sentiment_url": "https://sharemaestro.com/sentiment/2b54e02b-1441-43ca-8cf6-5798bc73166f/"}]}}, {"id": "source:3b4bb3bfa2aeeb1779e1082732bd276bb432e377cedb62ce6429dcf023f12012", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOVFBucS14bElnc3YzWU9INHhDNjBHZnVEaXE1Z2E5M0o2UUk4MFRTRnVoS3hnTHRjUzMxMjRNTnMzcXVIZ29wOHJqWU5aMmhTaHRCMEtBN08wbTE0NDFNdDg1RlhvNGc4bDFZZTZHZWxwME91T2w2UkstUkNsa2RpV1BicHNPQnNiclJnb0xBRURGUGwwcHRtRGZ0aFBmeG1Nb0dxNm1n?oc=5", "external_url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOVFBucS14bElnc3YzWU9INHhDNjBHZnVEaXE1Z2E5M0o2UUk4MFRTRnVoS3hnTHRjUzMxMjRNTnMzcXVIZ29wOHJqWU5aMmhTaHRCMEtBN08wbTE0NDFNdDg1RlhvNGc4bDFZZTZHZWxwME91T2w2UkstUkNsa2RpV1BicHNPQnNiclJnb0xBRURGUGwwcHRtRGZ0aFBmeG1Nb0dxNm1n?oc=5", "title": "Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update", "content_text": "Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update", "date_published": "2026-08-14T15:00:00+00:00", "authors": [{"name": "Market source"}], "tags": ["Earnings", "JSPR"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "JSPR", "name": "Jasper Therapeutics Inc", "sentiment_url": "https://sharemaestro.com/sentiment/e6bc52d4-759d-4082-a252-e3fd6873465d/"}]}}, {"id": "source:995c6c8e9ce316ac7641842f05367a64411dcd6ed04b56fb9d9824e0e977d37f", "url": "https://www.marketbeat.com/instant-alerts/alumis-nasdaqalms-shares-gap-down-after-earnings-miss-2026-08-14", "external_url": "https://www.marketbeat.com/instant-alerts/alumis-nasdaqalms-shares-gap-down-after-earnings-miss-2026-08-14", "title": "Alumis (NASDAQ:ALMS) Shares Gap Down After Earnings Miss", "content_text": "Alumis Inc. (NASDAQ:ALMS) experienced a significant share price drop after reporting disappointing earnings, missing both revenue and EPS consensus estimates. Despite the poor financial results and insider selling, analyst sentiment remains largely positive with a \"Moderate Buy\" consensus rating and a target price of $40.30. Several institutional investors, including BlackRock and Spruce Street Capital, recently established new positions in the company, while insiders sold a notable number of shares.", "date_published": "2026-08-14T14:33:50+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Earnings", "ALMS"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ALMS", "name": "Alumis Inc", "sentiment_url": "https://sharemaestro.com/sentiment/8cec622b-babf-4237-9cff-7bf5beb510ad/"}]}}, {"id": "source:f416de22cf631a3dbb7c98bcacc462420785fb07888215087741b995fd8451b6", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPUlJxM1AtejljN2h0cGs2UU00SEdzcnJ3VERvNFdhOUEzUHpaNHczSzgzOC1RY0QtS0dDUHhaODNwZXhnTVF1VmZHOXBKVmxZRFNHUmFFY294Vm92R29VMHJ3S2xhcGhfQUIxaXVKUHg2U1FGakExcDJ0dWtEc3VLMDhWalJsMVl0MThnOXpTVF9VbU1qcEQ3SHppN210WkpzTFZrOUxCWmNkWGx5SFhZQmFQNy1PQQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPUlJxM1AtejljN2h0cGs2UU00SEdzcnJ3VERvNFdhOUEzUHpaNHczSzgzOC1RY0QtS0dDUHhaODNwZXhnTVF1VmZHOXBKVmxZRFNHUmFFY294Vm92R29VMHJ3S2xhcGhfQUIxaXVKUHg2U1FGakExcDJ0dWtEc3VLMDhWalJsMVl0MThnOXpTVF9VbU1qcEQ3SHppN210WkpzTFZrOUxCWmNkWGx5SFhZQmFQNy1PQQ?oc=5", "title": "Celcuity (NASDAQ:CELC) Shares Gap Down on Disappointing Earnings", "content_text": "Celcuity (NASDAQ:CELC) Shares Gap Down on Disappointing Earnings", "date_published": "2026-08-14T14:33:44+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Earnings", "CELC"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "CELC", "name": "Celcuity LLC", "sentiment_url": "https://sharemaestro.com/sentiment/c797b78b-4fee-4542-836b-4cb097d61c43/"}]}}, {"id": "source:da5fdbca2e58c10287957137233a8a2cd6091ae287ee542fad5f60f816b3092b", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNN0h5d1g1YTI4d3pjc0s0QlpEcUV0dGhBRWJoTHpDUGxXYXY1bWhFYmZTSTNxME5qclVrSC1xaTlaS2YxcGRZSmdEVGdCRThrNFBPX003WDliZGpVTjl1X0JoQnhYTG9ZSUpnTWFVaUp5ZGRpOUxEa0R3SnNrcFdGQWdJXzZJZVRpdUhZY2Q3WDhyYS1oTjUzaVFETXg5cXV2NVlOMWdvSQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNN0h5d1g1YTI4d3pjc0s0QlpEcUV0dGhBRWJoTHpDUGxXYXY1bWhFYmZTSTNxME5qclVrSC1xaTlaS2YxcGRZSmdEVGdCRThrNFBPX003WDliZGpVTjl1X0JoQnhYTG9ZSUpnTWFVaUp5ZGRpOUxEa0R3SnNrcFdGQWdJXzZJZVRpdUhZY2Q3WDhyYS1oTjUzaVFETXg5cXV2NVlOMWdvSQ?oc=5", "title": "U.S. Stock Futures Mixed, Heads for a Winning Week", "content_text": "Wall Street is headed for a winning week in which the S&P 500 has recorded a new all-time high. The Department of Commerce reported that retail sales decreased 0.6% in July. The Zacks Consensus Estimate was for a breakeven. The metric for June was 0.2%. However, retail sales increased 5% annually in July. Retail sales (excluding auto) decreased 0.3% last month. The Zacks Consensus Estimate was for an increase of 0.1%. The metric for June decreased 0.2%. Earnings News: AMAT, NKTR, STNE Applied Materials Inc. AMAT came up with quarterly adjusted earnings of $3.5 per share, beating the Zacks Cons", "date_published": "2026-08-14T14:29:00+00:00", "authors": [{"name": "TradingView"}], "tags": ["Earnings", "NKTR"], "_sharemaestro": {"country": "United States", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "NKTR", "name": "Nektar Therapeutics", "sentiment_url": "https://sharemaestro.com/sentiment/2b54e02b-1441-43ca-8cf6-5798bc73166f/"}]}}, {"id": "source:0232e1818a2262940ce313476d83124486d8af8b502f4410f3738a37ae7a29cd", "url": "https://news.google.com/rss/articles/CBMiYEFVX3lxTE9yRXV1em9kd2xsMVNQVjB5MDI0YjZVNnhtZk1vT0stX1haQWRpR2NFU2pFUjR3VGRFOEZMdEk0NDZFQzRQeHd3aVhCRTNxcmd2NzExSjBKd2FCejJjZTk5QQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiYEFVX3lxTE9yRXV1em9kd2xsMVNQVjB5MDI0YjZVNnhtZk1vT0stX1haQWRpR2NFU2pFUjR3VGRFOEZMdEk0NDZFQzRQeHd3aVhCRTNxcmd2NzExSjBKd2FCejJjZTk5QQ?oc=5", "title": "DFTX News Today | Why did Definium Therapeutics stock go down today?", "content_text": "DFTX News Today | Why did Definium Therapeutics stock go down today?", "date_published": "2026-08-14T14:04:46+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Market update", "DFTX"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "DFTX", "name": "Definium Therapeutics, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/ba04ea8d-2432-48e8-bb8d-11449de0c763/"}]}}, {"id": "source:1c8e2b70eafba878801ca3a51f697557dfb1c1fab92b551391c865d410bf518b", "url": "https://www.prnewswire.com/news-releases/ardx-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-ardelyx-302851485.html", "external_url": "https://www.prnewswire.com/news-releases/ardx-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-ardelyx-302851485.html", "title": "ARDX SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Ardelyx", "content_text": "SueWallSt has initiated an investigation into potential securities law violations by Ardelyx (NASDAQ: ARDX) following a significant drop in its stock price. The company lowered its 2026 IBSRELA revenue guidance by up to $80 million and withdrew its long-term XPHOZAH revenue target, citing payer utilization-management restrictions. This guidance cut led to an almost 18% decline in Ardelyx shares on August 7, 2026, prompting concerns about the adequacy of its disclosures regarding payer coverage.", "date_published": "2026-08-14T13:40:52+00:00", "authors": [{"name": "PR Newswire"}], "tags": ["Regulatory and legal", "ARDX"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ARDX", "name": "Ardelyx Inc", "sentiment_url": "https://sharemaestro.com/sentiment/c293609b-7203-452c-9f0a-7f8bc7bfa84d/"}]}}, {"id": "source:01568b04305a389424c649a04a45f3bb48b8f6820e94f01f26ede8df87a8b85a", "url": "https://news.google.com/rss/articles/CBMi6AFBVV95cUxNQ0RaRWF3QmQ3c1JwdFdSWElJNjl6ZXdrOGJycjd5VXkzclg3VFZMMEN4eklyLVdjZ3hYbGg2cW5YM3JMSWQwNmNycHZtakRKaldVeklQRUx3bnJWa09MTUM5YU9kTm0xSWZLZmZEYXp5R2hYcGJfSktDaGtpQ1ZKdnZxd2tLbHdpVFk5bG10Y2lBWUtfbHh5eTlZQnQ0ZzE3d2tHaXhlZTM2WVVmSER0S2pnanVWdVpIOGdhbFZJOWw0RjBnZGdYTEVhcnQwbjYtY04ySUxxLWJmUGRrc2N2Z1JoTDJTMEM50gHuAUFVX3lxTE4yUVFQNVVKQzYyeU5qQllWb2NqelpYbHA0UE91Smx0eDQ2ZEdlbjRMcjVIUmNNUndlaDlnWV9kbUVCaEhHTVZLMWF6M3RsZDBvVGRZUHVvOGQ5bWlpVmdwTV84ejBnT3luSUl0VUk3Umo3bzBsal9iankwbEw5enBlLTJRdmNGQ2gybmhOSW83YnF0NXFhSHdXVmlQWjNhaE9NeUxaNWo5dFlxVjMwRXdkblVwYklTWXRhVmwxT3NwbVNPRFNxRmhvTFZPRzdxUzc4MzNWX1gzM0VUNjFrazQ3aUJrYkRYZ1BId1NXLUE?oc=5", "external_url": "https://news.google.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?oc=5", "title": "Is Phase III Rezpegaldesleukin And Cash Runway Progress Altering The Investment Case For Nektar Therapeutics (NKTR)?", "content_text": "Is Phase III Rezpegaldesleukin And Cash Runway Progress Altering The Investment Case For Nektar Therapeutics (NKTR)?", "date_published": "2026-08-14T13:36:38+00:00", "authors": [{"name": "simplywall.st"}], "tags": ["Balance sheet", "NKTR"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "NKTR", "name": "Nektar Therapeutics", "sentiment_url": "https://sharemaestro.com/sentiment/2b54e02b-1441-43ca-8cf6-5798bc73166f/"}]}}, {"id": "source:8dc71079705610a28482643141072be9f4ca1d8b708f06563b733048af9fa884", "url": "https://ca.finance.yahoo.com/news/biomarin-pharmaceutical-bmrn-outperforming-other-134002976.html", "external_url": "https://ca.finance.yahoo.com/news/biomarin-pharmaceutical-bmrn-outperforming-other-134002976.html", "title": "Is BioMarin Pharmaceutical (BMRN) Outperforming Other Medical Stocks This Year?", "content_text": "BioMarin Pharmaceutical (BMRN) is outperforming the Medical sector and its specific industry year-to-date, with a 15.3% return compared to the sector's 3%. The company holds a Zacks Rank #2 (Buy) due to improving analyst sentiment. Cardinal Health (CAH) is another medical stock showing strong performance within the sector.", "date_published": "2026-08-14T13:13:12+00:00", "authors": [{"name": "Yahoo! Finance Canada"}], "tags": ["Earnings", "BMRN"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BMRN", "name": "Biomarin Pharmaceutical Inc", "sentiment_url": "https://sharemaestro.com/sentiment/8bde399a-c5bb-4592-bb6b-ac3d129b9feb/"}]}}, {"id": "source:8ecc71e5b3427760d6e2b90b96fce54588bfd8b7468363511d6c6dbca4d0c59a", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxOZkp6aTdaWUhLUExHQUxKVjRqS1hEZmJKVTJaYzhCM1ppNndtRS1qaG5RcGtraThjdEdRM3k5WWhyOWlzcmJocTVrZk94VzQ0bEJsN3U0dTFhUldUeHFDQ1ZTc191OE9FdUc3RDlQd0Y4YzZ2M2lCRFM2cVQzaGpybkJiV3dfcnd0a0M2ejFGQjdIOUltQU55M2VEZmo3b1FQTUJxd2J2SzJfanVYN201dzFDZw?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxOZkp6aTdaWUhLUExHQUxKVjRqS1hEZmJKVTJaYzhCM1ppNndtRS1qaG5RcGtraThjdEdRM3k5WWhyOWlzcmJocTVrZk94VzQ0bEJsN3U0dTFhUldUeHFDQ1ZTc191OE9FdUc3RDlQd0Y4YzZ2M2lCRFM2cVQzaGpybkJiV3dfcnd0a0M2ejFGQjdIOUltQU55M2VEZmo3b1FQTUJxd2J2SzJfanVYN201dzFDZw?oc=5", "title": "Capricor Therapeutics (CAPR) Stock Surges on FDA Application Ame", "content_text": "Capricor Therapeutics (CAPR) Stock Surges on FDA Application Ame", "date_published": "2026-08-14T12:54:24+00:00", "authors": [{"name": "GuruFocus"}], "tags": ["Market update", "CAPR"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "CAPR", "name": "Capricor Therapeutics Inc", "sentiment_url": "https://sharemaestro.com/sentiment/e2b47bef-4e47-4d5a-b1b8-a7d99654827c/"}]}}, {"id": "source:f4c081796fb4562df8a7d734c2d0370a2f9e422b46a27c1814deafefda332855", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOd2pVZS1jM1cxRUR2RGV6UE9YYkUtYUxBN1BocHd1Q2lDazhhdWhOVTdrMmJEMnk0TDJ4bHFlV2tZUjJKM01aNDVSamJmX0hPal9BYVBvQ1pVS3hvREtEWVVuR2RDWmh2bzlITFI5SGlUa1RlU3FNWjdMU1FiWnJWQXZrSmFKdE9RbHpGOUVSYWV3YXZPaS05aGU4Uk1zQk03RGc?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOd2pVZS1jM1cxRUR2RGV6UE9YYkUtYUxBN1BocHd1Q2lDazhhdWhOVTdrMmJEMnk0TDJ4bHFlV2tZUjJKM01aNDVSamJmX0hPal9BYVBvQ1pVS3hvREtEWVVuR2RDWmh2bzlITFI5SGlUa1RlU3FNWjdMU1FiWnJWQXZrSmFKdE9RbHpGOUVSYWV3YXZPaS05aGU4Uk1zQk03RGc?oc=5", "title": "Brokers Offer Predictions for RAPP Q1 Earnings", "content_text": "Brokers Offer Predictions for RAPP Q1 Earnings", "date_published": "2026-08-14T12:48:55+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Earnings", "RAPP"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "RAPP", "name": "Rapport Therapeutics, Inc. Common Stock", "sentiment_url": "https://sharemaestro.com/sentiment/8b163fdd-848f-4c1a-a72f-3a391c70131b/"}]}}, {"id": "source:e9b9d3cdb3c73c3a6b796ad0759560745bc4aa39bceaa57483269b6f7e630c5d", "url": "https://www.globenewswire.com/news-release/2026/08/14/3345313/0/en/bicara-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4.html", "external_url": "https://www.globenewswire.com/news-release/2026/08/14/3345313/0/en/bicara-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4.html", "title": "Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)", "content_text": "Bicara Therapeutics Inc. announced an inducement grant to Jennifer Larson, its new Chief Financial Officer, effective August 12, 2026. Ms. Larson received a non-qualified stock option to purchase 285,000 shares of common stock at an exercise price of $24.63 per share, vesting over approximately four years. This grant was made under Bicara's 2026 Inducement Plan and was approved by independent directors as a material inducement for her employment, in accordance with Nasdaq Listing Rule 5635(c)(4).", "date_published": "2026-08-14T12:42:44+00:00", "authors": [{"name": "GlobeNewswire"}], "tags": ["Market update", "BCAX"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BCAX", "name": "Bicara Therapeutics Inc. Common Stock", "sentiment_url": "https://sharemaestro.com/sentiment/cba9d64e-eba8-4722-8bbf-6786a467b60c/"}]}}, {"id": "source:61d3a584c875424c40f3d615c3cc585e20c037ec749945ccda6dcc4d7c290050", "url": "https://www.tradingview.com/news/tradingview:9e3879d675d45:0-vistagen-reports-q1-fy2027-1-48m-revenue-13-0m-net-loss-31-7m-cash-at-june-30-2026", "external_url": "https://www.tradingview.com/news/tradingview:9e3879d675d45:0-vistagen-reports-q1-fy2027-1-48m-revenue-13-0m-net-loss-31-7m-cash-at-june-30-2026", "title": "Vistagen reports Q1 FY2027: $1.48M revenue, $13.0M net loss, $31.7M cash at June 30, 2026", "content_text": "Vistagen announced its Q1 FY2027 results, reporting $1.476 million in revenue and a net loss of $13.03 million. The company ended the quarter with $31.7 million in cash, expecting these funds to support operations into 2027. Vistagen also highlighted upcoming FDA discussions regarding a potential Phase 3 pathway for fasedienol in social anxiety disorder.", "date_published": "2026-08-14T12:40:18+00:00", "authors": [{"name": "TradingView"}], "tags": ["Earnings", "VTGN"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "VTGN", "name": "VistaGen Therapeutics Inc", "sentiment_url": "https://sharemaestro.com/sentiment/de72e54f-253a-4fd9-9a77-4075aac4d646/"}]}}, {"id": "source:5057c21dc12b0b51c6447118c1812c11f9170b8515dcb5ede3aa28fca39dc395", "url": "https://ca.investing.com/news/stock-market-news/form-8k-vistagen-therapeutics-inc-for-14-august-93CH-4801401", "external_url": "https://ca.investing.com/news/stock-market-news/form-8k-vistagen-therapeutics-inc-for-14-august-93CH-4801401", "title": "Form 8K VistaGen Therapeutics Inc For: 14 August By Investing.com", "content_text": "This article announces that VistaGen Therapeutics Inc. has filed a Form 8K on August 14th. The brief news item from Investing.com provides no further details about the content of the filing but notes the stock symbol VTGN.", "date_published": "2026-08-14T12:40:17+00:00", "authors": [{"name": "Investing.com Canada"}], "tags": ["Earnings", "VTGN"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "VTGN", "name": "VistaGen Therapeutics Inc", "sentiment_url": "https://sharemaestro.com/sentiment/de72e54f-253a-4fd9-9a77-4075aac4d646/"}]}}, {"id": "source:af625e5cb4bad1729de90587785da904be2302fd05b0fd19b2d8eca922035ef7", "url": "https://www.globenewswire.com/news-release/2026/08/14/3345334/0/en/vistagen-reports-fiscal-year-2027-first-quarter-financial-results-and-corporate-update.html", "external_url": "https://www.globenewswire.com/news-release/2026/08/14/3345334/0/en/vistagen-reports-fiscal-year-2027-first-quarter-financial-results-and-corporate-update.html", "title": "Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update", "content_text": "Vistagen announced its fiscal year 2027 first-quarter financial results, highlighting progress in its fasedienol program for social anxiety disorder, including plans for FDA engagement regarding a Phase 3 pathway. The company reported a net loss of $13.0 million, reduced R&D and G&A expenses due to cash preservation, and a cash position of $31.7 million, which is expected to fund operations into 2027. Additionally, Vistagen made strategic appointments to its leadership team to support late-stage drug development.", "date_published": "2026-08-14T12:40:17+00:00", "authors": [{"name": "GlobeNewswire"}], "tags": ["Earnings", "VTGN"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "VTGN", "name": "VistaGen Therapeutics Inc", "sentiment_url": "https://sharemaestro.com/sentiment/de72e54f-253a-4fd9-9a77-4075aac4d646/"}]}}, {"id": "source:354c3518d5072237f2f7738b2cf5fe768ada95f473d17c6007c6ae15b4fd6cd5", "url": "https://www.stocktitan.net/sec-filings/ANAB/schedule-13g-a-anaptysbio-inc-amended-passive-investment-disclosure-80abae4a6120.html", "external_url": "https://www.stocktitan.net/sec-filings/ANAB/schedule-13g-a-anaptysbio-inc-amended-passive-investment-disclosure-80abae4a6120.html", "title": "Sirenia Capital discloses 5.0% AnaptysBio (ANAB) ownership in Schedule 13G/A", "content_text": "Sirenia Capital Management LP and Alex Silverstein have reported a beneficial ownership of 5.0% in AnaptysBio, Inc. (ANAB) common stock, as detailed in a Schedule 13G/A filing. This stake amounts to 1,491,959 shares, based on 29,608,481 shares outstanding as of June 22, 2026. The shares are held in a managed account of Point72 Associates II, LLC, with Sirenia and Mr. Silverstein exercising shared voting and dispositive power.", "date_published": "2026-08-14T12:39:56+00:00", "authors": [{"name": "Stock Titan"}], "tags": ["Market update", "ANAB"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ANAB", "name": "AnaptysBio Inc", "sentiment_url": "https://sharemaestro.com/sentiment/26217278-1163-474b-86e4-9fa390517fd6/"}]}}, {"id": "source:0208eb459a1be15ec46c063301d6295472a4da74719212aa10cac39407a11656", "url": "https://seekingalpha.com/news/4633193-vistagen-therapeutics-gaap-eps-of--030-beats-by-006-revenue-of-148m-beats-by-131m?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "external_url": "https://seekingalpha.com/news/4633193-vistagen-therapeutics-gaap-eps-of--030-beats-by-006-revenue-of-148m-beats-by-131m?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "title": "VistaGen Therapeutics GAAP EPS of -$0.30 beats by $0.06, revenue of $1.48M beats by $1.31M", "content_text": "* VistaGen Therapeutics press release [https://seekingalpha.com/pr/20619736-vistagen-reports-fiscal-year-2027-first-quarter-financial-results-and-corporate-update] (VTGN [https://seekingalpha.com/symbol/VTGN]): Q1 GAAP EPS of -$0.30 beats by $0.06. * Revenue of $1.48M (+516.7% Y/Y) beats by $1.31M. * Cash, cash equivalents, and marketable securities were $31.7 million as of June 30, 2026. Based on current operating plans, Vistagen believes its cash, cash equivalents, and marketable securities will be sufficient to fund operations into 2027 but are not expected to be sufficient to extend the Co", "date_published": "2026-08-14T12:33:59+00:00", "authors": [{"name": "seekingalpha.com"}], "tags": ["Earnings", "VTGN"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "VTGN", "name": "VistaGen Therapeutics Inc", "sentiment_url": "https://sharemaestro.com/sentiment/de72e54f-253a-4fd9-9a77-4075aac4d646/"}]}}, {"id": "source:825520dbb9cfa5036a9958e323f30cdb6e8cb71e4c643a7ff9169463b07a2b82", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNU2VTSTE4ZGFGQk1kSjYyYjNTRmpEYlNic3lwVHVERVF6dVBFSG83cnRPTW83VGFnQ2hSUkg0dTZFUFk0WldPeHF2T050OTRpQ3dMdWV3YTFVYUNrSzIwT3MyalF3Ujh2TXdhbldIS3JDRlFKLXBSa2JOTFljRGltU1lMMzlCN1RlVEt2VkVraE41UnVUODlNMzNCSjJUN20zMm1pRGdYd3ZQT1NuVGc?oc=5", "external_url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNU2VTSTE4ZGFGQk1kSjYyYjNTRmpEYlNic3lwVHVERVF6dVBFSG83cnRPTW83VGFnQ2hSUkg0dTZFUFk0WldPeHF2T050OTRpQ3dMdWV3YTFVYUNrSzIwT3MyalF3Ujh2TXdhbldIS3JDRlFKLXBSa2JOTFljRGltU1lMMzlCN1RlVEt2VkVraE41UnVUODlNMzNCSjJUN20zMm1pRGdYd3ZQT1NuVGc?oc=5", "title": "HC Wainwright Predicts Septerna's Q3 Earnings (NASDAQ:SEPN)", "content_text": "HC Wainwright Predicts Septerna's Q3 Earnings (NASDAQ:SEPN)", "date_published": "2026-08-14T12:19:51+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Earnings", "SEPN"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "SEPN", "name": "Septerna, Inc. Common Stock", "sentiment_url": "https://sharemaestro.com/sentiment/f9a7520a-53c1-4ef9-b2aa-b54424be1e31/"}]}}, {"id": "source:7ec087eb33cefe28036fb6d2aa257c4cf3d0b5687e8bf1dc5f72e000a355d14f", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPUFBSUXcxMzg4NmNOeG9HeThKSmt3RHF3MEU2elJmWWZ2UXh4VFRmY3RUekpDa0lFaUpVYktmVUpWbmRqcEtPMURYeFc4RzJxdlp0cWJtVzU4YTdrTVhuVXNNZFk4VW9rMWlYekU1a0dGM0h1VXRyZ3RKRGtBQVdJYUpOaldzM3hsVlpLQ3RxcnROblkxeXZGb3p4VC1NWEYwaG9yTVdla0VjbHB0VW9zeVNGQQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPUFBSUXcxMzg4NmNOeG9HeThKSmt3RHF3MEU2elJmWWZ2UXh4VFRmY3RUekpDa0lFaUpVYktmVUpWbmRqcEtPMURYeFc4RzJxdlp0cWJtVzU4YTdrTVhuVXNNZFk4VW9rMWlYekU1a0dGM0h1VXRyZ3RKRGtBQVdJYUpOaldzM3hsVlpLQ3RxcnROblkxeXZGb3p4VC1NWEYwaG9yTVdla0VjbHB0VW9zeVNGQQ?oc=5", "title": "Research Analysts Set Expectations for MannKind Q3 Earnings", "content_text": "Research Analysts Set Expectations for MannKind Q3 Earnings", "date_published": "2026-08-14T12:17:56+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Earnings", "MNKD"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MNKD", "name": "MannKind Corp", "sentiment_url": "https://sharemaestro.com/sentiment/ea6f90ee-f127-429e-b2af-8d9e4052576e/"}]}}, {"id": "source:ae22841550540a481007f295c12653ac3b4766b9f47ccf30b5f09f0ea05e66f0", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOaUc3QjFHWlh6dENncjI5V0Y3NlFrRC14c2xFT3NWQnNRUHA5bWFjbzVDLUVWZWZSWnI1bkFobEdsZlhmekYydVNFMUYwcXNCMlY0am5wd29qeVR0eVhQN1N1dmVsclRoR1duRmZMUnZSUzlja1FUSVJ6NGdkZlVtZ1k4TFJTRFNZMWZ6Q0t5anpIUlhQWUtGT0E3SVU2Vk15c1RuRGRLcXQ4MkJYbnJnVlJWckQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOaUc3QjFHWlh6dENncjI5V0Y3NlFrRC14c2xFT3NWQnNRUHA5bWFjbzVDLUVWZWZSWnI1bkFobEdsZlhmekYydVNFMUYwcXNCMlY0am5wd29qeVR0eVhQN1N1dmVsclRoR1duRmZMUnZSUzlja1FUSVJ6NGdkZlVtZ1k4TFJTRFNZMWZ6Q0t5anpIUlhQWUtGT0E3SVU2Vk15c1RuRGRLcXQ4MkJYbnJnVlJWckQ?oc=5", "title": "HC Wainwright Issues Negative Forecast for Immunome Earnings", "content_text": "HC Wainwright Issues Negative Forecast for Immunome Earnings", "date_published": "2026-08-14T12:17:56+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Earnings", "IMNM"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "IMNM", "name": "Immunome\u00a0Inc", "sentiment_url": "https://sharemaestro.com/sentiment/c3a1b4db-d1a5-47db-9ae2-1b33c6761682/"}]}}, {"id": "source:aece32cbceb89690dda7a95a948f5c558c8baa9211a9ec2cdde2a081b4c11af6", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOYWVtU1ltZ2FyZWM2WEQ4dWxjYW1kQWsxZjhKVDJubFY3NDFvS3ZuZURyUEhwR0F4SWRvUWxPdjE5WVN0YVNpOU90em5oR25FX19EbkRLeG9jZ05qd09aYkw2NFFwa2E5UnZTZnFmMVROY2ExSk5WUWZyUnVGZURLVlR0aDVYR3pKX2R2TW9NWk9qWGwwTHVHQ3BEcFJIemdVNzNXcy1uYkR4U0ZoXy0zcGN1UlliTFZYOEJFbG1nWDlWWWpu?oc=5", "external_url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOYWVtU1ltZ2FyZWM2WEQ4dWxjYW1kQWsxZjhKVDJubFY3NDFvS3ZuZURyUEhwR0F4SWRvUWxPdjE5WVN0YVNpOU90em5oR25FX19EbkRLeG9jZ05qd09aYkw2NFFwa2E5UnZTZnFmMVROY2ExSk5WUWZyUnVGZURLVlR0aDVYR3pKX2R2TW9NWk9qWGwwTHVHQ3BEcFJIemdVNzNXcy1uYkR4U0ZoXy0zcGN1UlliTFZYOEJFbG1nWDlWWWpu?oc=5", "title": "Mizuho raises Belite Bio stock price target to $220 on NDA progress", "content_text": "Mizuho raises Belite Bio stock price target to $220 on NDA progress", "date_published": "2026-08-14T12:16:19+00:00", "authors": [{"name": "Investing.com"}], "tags": ["Analyst action", "BLTE"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BLTE", "name": "Belite Bio Inc ADR", "sentiment_url": "https://sharemaestro.com/sentiment/623924bc-d175-483e-98a6-d82304cdb374/"}]}}, {"id": "source:01198b51c04c276d2cf844c8e445d30e012b41ef88aa54687d4596f739308e92", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOTGxLc2g1T1pKOU4ySDlsazNZY2ZoeDFyZWtjTmFreHlYeXVCa3h0bUJVYzVmS1VUZ1pfT2FyR2JoZXc5Y0JWMlg3Tk1rUDJ6b3M0emlFSnJEVFBkTmdLVzNjclVia05Sc2hKTHJMNkpOaEFKWVhmVnVfVXpRby1VRy0wSW9WTDNWYjBQdkIyWmtQU2hYUzFwYUNVZ0JkT3E1VXVGV3Jva0g2V1k?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOTGxLc2g1T1pKOU4ySDlsazNZY2ZoeDFyZWtjTmFreHlYeXVCa3h0bUJVYzVmS1VUZ1pfT2FyR2JoZXc5Y0JWMlg3Tk1rUDJ6b3M0emlFSnJEVFBkTmdLVzNjclVia05Sc2hKTHJMNkpOaEFKWVhmVnVfVXpRby1VRy0wSW9WTDNWYjBQdkIyWmtQU2hYUzFwYUNVZ0JkT3E1VXVGV3Jva0g2V1k?oc=5", "title": "Evaxion (NASDAQ: EVAX) sets August 20 call for Q2 2026 results and update", "content_text": "Evaxion (NASDAQ: EVAX) sets August 20 call for Q2 2026 results and update", "date_published": "2026-08-14T12:05:57+00:00", "authors": [{"name": "Stock Titan"}], "tags": ["Earnings", "EVAX"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "EVAX", "name": "Evaxion Biotech AS", "sentiment_url": "https://sharemaestro.com/sentiment/a6ab708f-0025-43c2-a164-bafa4475e8c2/"}]}}, {"id": "source:c8ede8fbac31b85508c11dd7482371dd87781f0aac1c69d6cc28449346b93547", "url": "https://www.stocktitan.net/sec-filings/KLRA/schedule-13g-kailera-therapeutics-inc-passive-investment-disclosure-5-6168bcbf82fb.html", "external_url": "https://www.stocktitan.net/sec-filings/KLRA/schedule-13g-kailera-therapeutics-inc-passive-investment-disclosure-5-6168bcbf82fb.html", "title": "RTW Investments discloses 8.3% Kailera Therapeutics (KLRA) stake on Schedule 13G", "content_text": "RTW Investments, LP and Roderick Wong, M.D. have reported an 8.3% beneficial ownership stake in Kailera Therapeutics, Inc. (KLRA) through a Schedule 13G filing. This amounts to 10,776,820 shares of common stock, based on 129,565,608 shares outstanding as of May 20, 2026. Both reporting persons share voting and dispositive power over these shares, which are held by RTW Funds, with RTW Investments acting as their investment adviser.", "date_published": "2026-08-14T12:04:27+00:00", "authors": [{"name": "Stock Titan"}], "tags": ["Deals and strategy", "KLRA"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "KLRA", "name": "Kailera Therapeutics, Inc. Common Stock", "sentiment_url": "https://sharemaestro.com/sentiment/5aad7a09-fe4a-41af-9f48-13cdece5f3e5/"}]}}, {"id": "source:8a4df3220b054156b94e1e78f3c681a8bcc34d8ad16b30e5caaef673f472a4ed", "url": "https://finance.yahoo.com/healthcare/articles/evaxion-announce-business-second-quarter-120000704.html", "external_url": "https://finance.yahoo.com/healthcare/articles/evaxion-announce-business-second-quarter-120000704.html", "title": "Evaxion to announce business update and second quarter 2026 financial results on August 20, 2026", "content_text": "Evaxion COPENHAGEN, Denmark, August 14, 2026 - Evaxion A/S (NASDAQ: EVAX) (\"Evaxion\"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology\u2122 platform, will provide a business update and report its second quarter 2026 financial results on Thursday August 20, 2026, before opening of the Nasdaq CM. Evaxion's Executive Management will host a conference call and webcast the same day at 14:30 CET/08:30 EST, presenting the update and results as well as taking questions. To join the conference call, listen to the presentation and ask verbal questions, please reg", "date_published": "2026-08-14T12:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "EVAX"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "EVAX", "name": "Evaxion Biotech AS", "sentiment_url": "https://sharemaestro.com/sentiment/a6ab708f-0025-43c2-a164-bafa4475e8c2/"}]}}, {"id": "source:5e8cb8d1db55de58109c566531b18d38719602ac17d59b9a8d046041f96b7326", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxQSnRHWDg2dXJDLTRLUU1DWE9sTXBrMVNVQUNtWFlvMWJnUWlMR29hdDlZVVVhajdnTlA5UXpBS1hWU3hmaWRUNkVGcGFNQkdqMllDXy01cENiMWl1QUlRREZ6WUhvRWdRS3RsbUZPV2FQSFRtWUJ3ZFVlVENPdG1LS2JtNFN5WU1GNUY3MzVYMHlJWEd5ZXFpMHNrSUFremlNYWdKTG4wbnA1SUFIOHVaRFBGNlFTOEJwZ3dDTmtIOUJma0dybXd6YWZPOUQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxQSnRHWDg2dXJDLTRLUU1DWE9sTXBrMVNVQUNtWFlvMWJnUWlMR29hdDlZVVVhajdnTlA5UXpBS1hWU3hmaWRUNkVGcGFNQkdqMllDXy01cENiMWl1QUlRREZ6WUhvRWdRS3RsbUZPV2FQSFRtWUJ3ZFVlVENPdG1LS2JtNFN5WU1GNUY3MzVYMHlJWEd5ZXFpMHNrSUFremlNYWdKTG4wbnA1SUFIOHVaRFBGNlFTOEJwZ3dDTmtIOUJma0dybXd6YWZPOUQ?oc=5", "title": "Kymera Therapeutics Stock 8-Day Winning Spree: Stock Climbs 14%", "content_text": "Kymera Therapeutics Stock 8-Day Winning Spree: Stock Climbs 14%", "date_published": "2026-08-14T11:25:19+00:00", "authors": [{"name": "Trefis"}], "tags": ["Market update", "KYMR"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "KYMR", "name": "Kymera Therapeutics Inc", "sentiment_url": "https://sharemaestro.com/sentiment/b900d6f5-bdf3-4a85-8519-c09cce792794/"}]}}, {"id": "source:c64b8e9316762e1768a52a06f503d2444de2b4638847742571fd283e0347bcb8", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxOenRDWG9XTjRfOWVPbnkyamJ5LWlTVDQycVhzWU4tRTYxenZHdEZlaGllYkI4OUF5MmJQLUNlSEViQTdlMUhmSWpBdHpMTzVYVVQ5UzlrN1BtNFd3azVQVjNSRXotTDB6ejZ6bkExLTQ2eHVTd1lnSkxtemoyYmdrYV83Y1lJV201azhnNEJoSkVIUk01NF9OWWJSVks3TlNMVkJfZk90b3BFSFdBZWhXWnRsYVNYbF9GQ0lUcnlFVjZyR0tIVDV6X0hkWXgwbXZMeGJ0UGZ3?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxOenRDWG9XTjRfOWVPbnkyamJ5LWlTVDQycVhzWU4tRTYxenZHdEZlaGllYkI4OUF5MmJQLUNlSEViQTdlMUhmSWpBdHpMTzVYVVQ5UzlrN1BtNFd3azVQVjNSRXotTDB6ejZ6bkExLTQ2eHVTd1lnSkxtemoyYmdrYV83Y1lJV201azhnNEJoSkVIUk01NF9OWWJSVks3TlNMVkJfZk90b3BFSFdBZWhXWnRsYVNYbF9GQ0lUcnlFVjZyR0tIVDV6X0hkWXgwbXZMeGJ0UGZ3?oc=5", "title": "Handelsbanken Fonder AB Purchases Shares of 160,900 Oruka Therapeutics, Inc. $ORKA", "content_text": "Handelsbanken Fonder AB Purchases Shares of 160,900 Oruka Therapeutics, Inc. $ORKA", "date_published": "2026-08-14T11:15:14+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Market update", "ORKA"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ORKA", "name": "Oruka Therapeutics, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/6d245a59-aaf2-49c2-b017-4ec0def04928/"}]}}, {"id": "source:a3f5e54b1bc513caabef40cd59e043b01a52e34e062487654650d578a673dedb", "url": "https://finance.yahoo.com/markets/stocks/articles/ligand-pharmaceuticals-lgnd-stock-trades-111117444.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/ligand-pharmaceuticals-lgnd-stock-trades-111117444.html", "title": "Ligand Pharmaceuticals (LGND) Stock Trades Below Fair Value Following A 337% Run", "content_text": "Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Ligand Pharmaceuticals stock has surged over the past five years, yet the valuation signals are split, with a Discounted Cash Flow (DCF) intrinsic value estimate pointing to meaningful upside while traditional market multiples suggest the shares are pricing in a richer outlook. Ligand Pharmaceuticals has delivered a very large 5 year return of 337.4%, which puts extra focus on whether the current price still offers a margin of safety. The recent expansion of its royalty portfolio ", "date_published": "2026-08-14T11:11:17+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "LGND"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "LGND", "name": "Ligand Pharmaceuticals Incorporated", "sentiment_url": "https://sharemaestro.com/sentiment/f1224815-cddd-4bfb-8dc3-fe2858461148/"}]}}, {"id": "source:1f8b9914f04672b63c5ce40d09f31d79487ae9eea3a8f6ca8f8859610efdca5d", "url": "https://www.stocktitan.net/sec-filings/ARQT/schedule-13g-arcutis-biotherapeutics-inc-passive-investment-disclosur-7109b0009dc7.html", "external_url": "https://www.stocktitan.net/sec-filings/ARQT/schedule-13g-arcutis-biotherapeutics-inc-passive-investment-disclosur-7109b0009dc7.html", "title": "Polar Capital discloses 5.28% Arcutis Biotherapeutics (ARQT) ownership in Schedule 13G", "content_text": "Polar Capital Holdings Plc and Polar Capital LLP have disclosed a 5.28% ownership stake in Arcutis Biotherapeutics, Inc. (ARQT) through a Schedule 13G filing. The investment firm beneficially owns 6,606,945 shares, with sole voting and dispositive power, based on Arcutis's 125,083,374 outstanding shares as of May 6, 2026. This filing indicates a passive investment intent, with the aggregated amount beneficially owned representing 5.28% of the class.", "date_published": "2026-08-14T10:42:27+00:00", "authors": [{"name": "Stock Titan"}], "tags": ["Deals and strategy", "ARQT"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ARQT", "name": "Arcutis Biotherapeutics\u00a0Inc", "sentiment_url": "https://sharemaestro.com/sentiment/3c4bc3fc-9a56-49a2-b297-d5d651099723/"}]}}, {"id": "source:f92f7f0c9693e24edb6712526166529b5a9529086404f842dfa5a969adb07aff", "url": "https://www.nasdaq.com/articles/ionis-stock-has-plunged-30-it-time-buy-beaten-down-stock", "external_url": "https://www.nasdaq.com/articles/ionis-stock-has-plunged-30-it-time-buy-beaten-down-stock", "title": "Ionis Stock Has Plunged 30%. Is It Time to Buy the Beaten-Down Stock?", "content_text": "Key Points Q2 revenue fell, but last year included a large one-time payment. There were other signs of trouble in the earnings report. Wall Street is still bullish on the shares.10 stocks we like better than Ionis Pharmaceuticals \u203a Shares of Ionis Pharmaceuticals(NASDAQ: IONS) fell from about $86 in July to roughly $56 today, and are down about 30% year to date. The drop can be traced back to its heart drug Eplontersen failing to prove its efficacy, but it's just one symptom in a vast array of potential issues outlined in its recent second-quarter report. Image source: Getty Images. Missed Nvi", "date_published": "2026-08-14T10:35:00+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Earnings", "ARWR"], "_sharemaestro": {"country": "United States", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ARWR", "name": "Arrowhead Pharmaceuticals Inc", "sentiment_url": "https://sharemaestro.com/sentiment/3b024d07-a80f-48f0-bbda-6bb79c593c64/"}]}}, {"id": "source:3a46ef33160b83e5f52ede04dc5697cd45ead01cf871b99e78447d3d14fec3a6", "url": "https://www.marketscreener.com/news/bernstein-adjusts-pt-on-regeneron-pharmaceuticals-to-756-from-753-maintains-market-perform-rating-ce7859dede89f527", "external_url": "https://www.marketscreener.com/news/bernstein-adjusts-pt-on-regeneron-pharmaceuticals-to-756-from-753-maintains-market-perform-rating-ce7859dede89f527", "title": "Bernstein Adjusts PT on Regeneron Pharmaceuticals to $756 From $753, Maintains Market Perform Rating", "content_text": "Bernstein has increased its price target for Regeneron Pharmaceuticals (REGN) to $756 from $753, while maintaining a \"Market Perform\" rating on the stock. This adjustment reflects a modest change in the analyst's valuation, indicating a continued neutral stance on the company's stock performance. The news is part of a series of recent analyst adjustments for Regeneron, with other firms also revising their price targets.", "date_published": "2026-08-14T10:16:14+00:00", "authors": [{"name": "marketscreener.com"}], "tags": ["Analyst action", "REGN"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "REGN", "name": "Regeneron Pharmaceuticals Inc", "sentiment_url": "https://sharemaestro.com/sentiment/1c42d613-c405-45d7-9f43-f2050c317cb4/"}]}}, {"id": "source:5442470d52af5831fe7474c6e726c09e5be26a87d0ba3521abe67699ae8022df", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxNVGRTODQ3ZHp4RE9PY0stcGt1NmNWZHBMXy1adkJXcnZab1NzaTF2RHczSUs2cHQyYjhFb19FelZ3R3E4NS1pZWJKMGxobTJMVF8tUWNqeFViX2JIUlRrMkRmQnlfaDNDaUxKRlRHYmlHMHNHMV9kSV9WNjJCeWhyVjM2WVktM05USXY4eGxjejVpaVR4U21td0o0ZjFwZUdIT1pXVWdPc2dQeTNuai0zUGdoMUJnbTg0b29HU3Bmb210aS13WjlGb1JTUVJ4SE9zWGlCNDhvX0FEYXNTaXlXWGtJNHdQOU0?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxNVGRTODQ3ZHp4RE9PY0stcGt1NmNWZHBMXy1adkJXcnZab1NzaTF2RHczSUs2cHQyYjhFb19FelZ3R3E4NS1pZWJKMGxobTJMVF8tUWNqeFViX2JIUlRrMkRmQnlfaDNDaUxKRlRHYmlHMHNHMV9kSV9WNjJCeWhyVjM2WVktM05USXY4eGxjejVpaVR4U21td0o0ZjFwZUdIT1pXVWdPc2dQeTNuai0zUGdoMUJnbTg0b29HU3Bmb210aS13WjlGb1JTUVJ4SE9zWGlCNDhvX0FEYXNTaXlXWGtJNHdQOU0?oc=5", "title": "Arcutis Biotherapeutics (NASDAQ:ARQT) Matches Navellier's Growth Playbook With Accelerating Fundamentals", "content_text": "Arcutis Biotherapeutics (NASDAQ:ARQT) Matches Navellier's Growth Playbook With Accelerating Fundamentals", "date_published": "2026-08-14T10:11:11+00:00", "authors": [{"name": "ChartMill"}], "tags": ["Market update", "ARQT"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ARQT", "name": "Arcutis Biotherapeutics\u00a0Inc", "sentiment_url": "https://sharemaestro.com/sentiment/3c4bc3fc-9a56-49a2-b297-d5d651099723/"}]}}, {"id": "source:a1c08db8606a81946dc96237a7ac91198a7e095d10966702d650985bf2911dba", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxORGc4NFNkeWk0SDZHVmFfZXp1QkRUaWhjdWpYUGRDb1lDOXE1LXY0VXBTdWY4ZF8wMVZUMlZOTzg3akcxWXV5YTg0bjFqSEk5c1RXTlRMVm1OMlRxQnlzMGhuZVNRNWpsbEduUHZ3T1FrWWgzRldDaWFQLWRsVlptTWFHWFBlZVMtV2s3YjRVdjNyLVRSZnVkSHU1ZjJIMjNmR29MOXpLRzdEZ01ZUnVVd0lwbWNpUFVSWEsxeENMYjRwSzJybWtR?oc=5", "external_url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxORGc4NFNkeWk0SDZHVmFfZXp1QkRUaWhjdWpYUGRDb1lDOXE1LXY0VXBTdWY4ZF8wMVZUMlZOTzg3akcxWXV5YTg0bjFqSEk5c1RXTlRMVm1OMlRxQnlzMGhuZVNRNWpsbEduUHZ3T1FrWWgzRldDaWFQLWRsVlptTWFHWFBlZVMtV2s3YjRVdjNyLVRSZnVkSHU1ZjJIMjNmR29MOXpLRzdEZ01ZUnVVd0lwbWNpUFVSWEsxeENMYjRwSzJybWtR?oc=5", "title": "Rallybio Corp (RLYB) sees Balyasny group report 0% ownership in 13G/A", "content_text": "Rallybio Corp (RLYB) sees Balyasny group report 0% ownership in 13G/A", "date_published": "2026-08-14T10:09:50+00:00", "authors": [{"name": "Stock Titan"}], "tags": ["Market update", "RLYB"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "RLYB", "name": "Rallybio Corp", "sentiment_url": "https://sharemaestro.com/sentiment/8ae7d703-1a45-4a80-8791-d5a3afec4d6d/"}]}}, {"id": "source:082e8bab81e6498c8f17ae7e3ed256a87a6f59e0f3b44b6d1d85d64fc3ee21f9", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNeVVUTjAwX1lqOEs2Z2hpVE5lNkZCN0t0Q3dfMk80SHJHelJPWnZnVXltZDl3dTNNTE5xNWJQTkJOTkpGbTBiUTRqY1NqVzkxZ3FKbWdoZFZyUmVVdzhybWU3MGJYTWR2cW5yNGVMVDlJWnp4U2hrZ1Z1MTMxdUtLUzhUVDFqMFRTVmJiRXRjSjU5T2FhTXhLdU1DRjBpeWxwN1l4N2pKSTZ5aU05LXJfaTZB?oc=5", "external_url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNeVVUTjAwX1lqOEs2Z2hpVE5lNkZCN0t0Q3dfMk80SHJHelJPWnZnVXltZDl3dTNNTE5xNWJQTkJOTkpGbTBiUTRqY1NqVzkxZ3FKbWdoZFZyUmVVdzhybWU3MGJYTWR2cW5yNGVMVDlJWnp4U2hrZ1Z1MTMxdUtLUzhUVDFqMFRTVmJiRXRjSjU5T2FhTXhLdU1DRjBpeWxwN1l4N2pKSTZ5aU05LXJfaTZB?oc=5", "title": "Nektar Therapeutics (NKTR) adds $1.02B cash while posting $85.5M loss", "content_text": "Nektar Therapeutics (NKTR) adds $1.02B cash while posting $85.5M loss", "date_published": "2026-08-14T10:07:07+00:00", "authors": [{"name": "Stock Titan"}], "tags": ["Balance sheet", "NKTR"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "NKTR", "name": "Nektar Therapeutics", "sentiment_url": "https://sharemaestro.com/sentiment/2b54e02b-1441-43ca-8cf6-5798bc73166f/"}]}}, {"id": "source:bc0aa0447507eaf7a69603997d50a911aa68fc7e6c66948128d59e4af20b5d30", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQLWhlc29YUkFub2RJLXA5dG5KQjczZWd1N0dvTzM1TVlyWGROdXRJSVB1SU0xaXNFOHhjcUdLdVJKOE1GRTlqNHEwWnFzRUFpbmxDek04c3JIZEhLTXJGblZvWFF2RVV0UDMyc2IyOG9HWmppWHU4T3lkSnhVek11QkdWMFpuM3dnMDg2WjdTWUZRZmkwdTNqY2JDcVdfcFNobHRZc1FIMmR4cXVsRGw1eHVyY2VoYnloWHJYMUlR?oc=5", "external_url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQLWhlc29YUkFub2RJLXA5dG5KQjczZWd1N0dvTzM1TVlyWGROdXRJSVB1SU0xaXNFOHhjcUdLdVJKOE1GRTlqNHEwWnFzRUFpbmxDek04c3JIZEhLTXJGblZvWFF2RVV0UDMyc2IyOG9HWmppWHU4T3lkSnhVek11QkdWMFpuM3dnMDg2WjdTWUZRZmkwdTNqY2JDcVdfcFNobHRZc1FIMmR4cXVsRGw1eHVyY2VoYnloWHJYMUlR?oc=5", "title": "MiNK Therapeutics (NASDAQ:INKT) Stock Rating Lowered by Zacks Research", "content_text": "MiNK Therapeutics (NASDAQ:INKT) Stock Rating Lowered by Zacks Research", "date_published": "2026-08-14T10:03:47+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Analyst action", "INKT"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "INKT", "name": "Mink Therapeutics Inc", "sentiment_url": "https://sharemaestro.com/sentiment/cc80f937-724a-42d1-a52d-0ddff4bf3d31/"}]}}, {"id": "source:eff5922e101371e66c6fa7e287bc65b5cf721f7fc28b7dab3b5aa6a295c6bcc3", "url": "https://finance.yahoo.com/markets/stocks/articles/zacks-com-featured-highlights-biomarin-093800634.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/zacks-com-featured-highlights-biomarin-093800634.html", "title": "Zacks.com featured highlights include BioMarin Pharmaceutical, Invesco, Centene Corporation, Hewlett Packard Enterprise and Gibraltar Industries", "content_text": "For Immediate Release Chicago, IL \u2013 August 14, 2026 \u2013 Stocks in this week's article are BioMarin Pharmaceutical BMRN, Invesco IVZ, Centene Corporation CNC, Hewlett Packard Enterprise HPE and Gibraltar Industries ROCK. 5 Undervalued Price-to-Book Stocks Worth Buying in August There are several different ways to find value stocks. Among these, the most popular are the price-to-earnings ratio (P/E) and the price-to-sales ratio (P/S). However, investors often overlook the price-to-book ratio (P/B ratio), which, though used less often, is also an easy-to-use valuation tool for identifying low-price", "date_published": "2026-08-14T09:38:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "BMRN"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BMRN", "name": "Biomarin Pharmaceutical Inc", "sentiment_url": "https://sharemaestro.com/sentiment/8bde399a-c5bb-4592-bb6b-ac3d129b9feb/"}]}}, {"id": "source:c3be8f4f07a620f71c13c5c9dd3defa6a15056f555d6e9f47abff232da37beb3", "url": "https://www.marketbeat.com/instant-alerts/arcutis-biotherapeutics-inc-nasdaqarqt-receives-average-recommendation-of-moderate-buy-from-brokerages-2026-08-14", "external_url": "https://www.marketbeat.com/instant-alerts/arcutis-biotherapeutics-inc-nasdaqarqt-receives-average-recommendation-of-moderate-buy-from-brokerages-2026-08-14", "title": "Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Receives Average Recommendation of \"Moderate Buy\" from Brokerages", "content_text": "Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) has received an average \"Moderate Buy\" recommendation from analysts, with an average 12-month price target of $35.57. The company recently exceeded quarterly earnings and revenue expectations, reporting $0.11 EPS against an anticipated $0.06 and $129.86 million in revenue versus $118.85 million. Despite positive analyst sentiment and strong financial performance, company insiders have sold approximately $803,066 worth of shares in the past 90 days.", "date_published": "2026-08-14T08:42:27+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Earnings", "ARQT"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ARQT", "name": "Arcutis Biotherapeutics\u00a0Inc", "sentiment_url": "https://sharemaestro.com/sentiment/3c4bc3fc-9a56-49a2-b297-d5d651099723/"}]}}, {"id": "source:19c9be3f32927a8d3c04f5a4e59371ec9cc10782e25cd1958fde71d85697f2ad", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxNaDdJQzZua2pJUWtBS2NUUjVUSlV3dWpqODdSRjRJTWFyWUxMVWJzeHRGYm1BSDVZaE4zNjZNbHVyMi0wVzJNdDdoNm1oODM2b3R6YWdIbVhnNjV5ZVNlYXV5ZGNEVVlMYV8zQUpMbEN6OWtTTlF4T194dWdwSGNlZ0JTaXo4OGZYc2F2TmJubW5pallxeUp2el9HdGlfVzNUNXlzei1raWhleHJIZC01dlNZMGhrSHdlWFJJaDZlZG0wN21TX2c?oc=5", "external_url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxNaDdJQzZua2pJUWtBS2NUUjVUSlV3dWpqODdSRjRJTWFyWUxMVWJzeHRGYm1BSDVZaE4zNjZNbHVyMi0wVzJNdDdoNm1oODM2b3R6YWdIbVhnNjV5ZVNlYXV5ZGNEVVlMYV8zQUpMbEN6OWtTTlF4T194dWdwSGNlZ0JTaXo4OGZYc2F2TmJubW5pallxeUp2el9HdGlfVzNUNXlzei1raWhleHJIZC01dlNZMGhrSHdlWFJJaDZlZG0wN21TX2c?oc=5", "title": "Sei Investments Co. Buys Shares of 99,627 MeiraGTx Holdings PLC $MGTX", "content_text": "Sei Investments Co. Buys Shares of 99,627 MeiraGTx Holdings PLC $MGTX", "date_published": "2026-08-14T08:42:14+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Market update", "MGTX"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MGTX", "name": "MeiraGTx Holdings PLC", "sentiment_url": "https://sharemaestro.com/sentiment/c17b2e70-74a3-4bc4-a406-6ee0fb32abf1/"}]}}, {"id": "source:81c8e4e17c60618383deb8097956c1364d7273e92aa5ffa4b850853d3a96c613", "url": "https://www.ktvb.com/article/syndication/associatedpress/nektar-q2-earnings-snapshot/616-39535fc2-28ac-4f67-bcf7-928bd77f38da", "external_url": "https://www.ktvb.com/article/syndication/associatedpress/nektar-q2-earnings-snapshot/616-39535fc2-28ac-4f67-bcf7-928bd77f38da", "title": "Nektar: Q2 Earnings Snapshot", "content_text": "The article provides a snapshot of Nektar's Q2 earnings. No specific financial details are available in the provided content, as the main article text was not included.", "date_published": "2026-08-14T08:40:29+00:00", "authors": [{"name": "KTVB"}], "tags": ["Earnings", "NKTR"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "NKTR", "name": "Nektar Therapeutics", "sentiment_url": "https://sharemaestro.com/sentiment/2b54e02b-1441-43ca-8cf6-5798bc73166f/"}]}}, {"id": "source:483dae81a8645750f94d73ba0194dddd2330f8746335755914527985d64a5d07", "url": "https://seekingalpha.com/news/4633059-sp500-nasdaq-dow-jones-outlook-stock-market?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "external_url": "https://seekingalpha.com/news/4633059-sp500-nasdaq-dow-jones-outlook-stock-market?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "title": "Stock index futures largely flat after S&P 500 closes at record high", "content_text": "[Wall Street New York stock exchange stock market] alexsl Stock index futures were muted on Friday after the S&P 500 closed at a record high in the previous session. Dow futures (INDU [https://seekingalpha.com/symbol/INDU]) -0.12%, S&P 500 futures (SPX [https://seekingalpha.com/symbol/SPX]) +0.02%, and Nasdaq futures (US100:IND) -0.24%. The S&P 500 reached another intraday record on Thursday as investors weighed July producer prices, which showed wholesale inflation was unchanged from the previous month. Investors will turn to July retail sales data at 8:30 a.m. ET for fresh clues on consumer ", "date_published": "2026-08-14T08:11:29+00:00", "authors": [{"name": "seekingalpha.com"}], "tags": ["Macro sensitivity", "INCY"], "_sharemaestro": {"country": "United States", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "INCY", "name": "Incyte Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/da05e924-2410-4fdc-ae9c-7a87bb611124/"}]}}, {"id": "source:b2ef18b4d8f0cd1aa0655b35a28a5b101a67f25da971894824ec3cdc46d379b4", "url": "https://www.marketbeat.com/instant-alerts/filing-dimensional-fund-advisors-lp-increases-stock-position-in-bicara-therapeutics-inc-bcax-2026-08-14", "external_url": "https://www.marketbeat.com/instant-alerts/filing-dimensional-fund-advisors-lp-increases-stock-position-in-bicara-therapeutics-inc-bcax-2026-08-14", "title": "Dimensional Fund Advisors LP Increases Stock Position in Bicara Therapeutics Inc. $BCAX", "content_text": "Dimensional Fund Advisors LP significantly increased its stake in Bicara Therapeutics Inc. by 166.9% in the first quarter, now holding 109,261 shares valued at $2.17 million. Several other institutional investors also raised their positions, while insider sales have occurred. Bicara Therapeutics maintains a \"Moderate Buy\" consensus rating with an average price target of $32.73, and investors are looking forward to clinical progress, particularly the planned 2026 enrollment for the ficerafusp alfa study.", "date_published": "2026-08-14T07:42:44+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Analyst action", "BCAX"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BCAX", "name": "Bicara Therapeutics Inc. Common Stock", "sentiment_url": "https://sharemaestro.com/sentiment/cba9d64e-eba8-4722-8bbf-6786a467b60c/"}]}}, {"id": "source:fd93c042346784094abb537321deddf077be0acbfce466301e0d9fa5dc8958a1", "url": "https://www.marketbeat.com/instant-alerts/filing-dimensional-fund-advisors-lp-sells-288067-shares-of-summit-therapeutics-plc-smmt-2026-08-14", "external_url": "https://www.marketbeat.com/instant-alerts/filing-dimensional-fund-advisors-lp-sells-288067-shares-of-summit-therapeutics-plc-smmt-2026-08-14", "title": "Dimensional Fund Advisors LP Sells 288,067 Shares of Summit Therapeutics PLC $SMMT", "content_text": "Dimensional Fund Advisors LP significantly reduced its stake in Summit Therapeutics PLC by 76.5% in the first quarter, selling over 288,000 shares. Despite this, Summit Therapeutics has seen strong insider buying, with executives acquiring 7.87 million shares worth approximately $103.6 million in the past three months. The company's stock opened down 7.3% at $14.00, and analysts currently have a consensus \"Hold\" rating with a target price of $24.25, following a missed EPS estimate.", "date_published": "2026-08-14T07:41:26+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Earnings", "SMMT"], "_sharemaestro": {"country": "United States", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "SMMT", "name": "Summit Therapeutics PLC", "sentiment_url": "https://sharemaestro.com/sentiment/dc902abc-ea97-40f7-98c2-416cf99620c7/"}]}}, {"id": "source:631eb9be6b053c9780549ecc854056c0c6fa451f5940a29fbe0cc6122488c3ad", "url": "https://www.marketbeat.com/instant-alerts/filing-dimensional-fund-advisors-lp-sells-12867-shares-of-rhythm-pharmaceuticals-inc-rytm-2026-08-14", "external_url": "https://www.marketbeat.com/instant-alerts/filing-dimensional-fund-advisors-lp-sells-12867-shares-of-rhythm-pharmaceuticals-inc-rytm-2026-08-14", "title": "Dimensional Fund Advisors LP Sells 12,867 Shares of Rhythm Pharmaceuticals, Inc. $RYTM", "content_text": "Dimensional Fund Advisors LP reduced its stake in Rhythm Pharmaceuticals, Inc. by 40.2% in the first quarter, selling 12,867 shares and retaining 19,151 shares valued at approximately $1.67 million. Despite the sale, Rhythm Pharmaceuticals reported strong quarterly revenue growth of 46.9% year-over-year and beat analyst estimates for its adjusted loss per share. The stock currently holds a \"Moderate Buy\" consensus rating from analysts, with an average price target of $142.44.", "date_published": "2026-08-14T07:41:22+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Earnings", "RYTM"], "_sharemaestro": {"country": "United States", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "RYTM", "name": "Rhythm Pharmaceuticals Inc", "sentiment_url": "https://sharemaestro.com/sentiment/f13208a9-5d26-4454-b1bb-175d72595ff1/"}]}}]}